The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering. One of the institute‘s main tasks is to conduct contract research for companies, hospitals and research institutes operating in the field of Cell and Gene Therapy Development.

With over 20 years of experience and a commitment to swiftly addressing customer needs, we have successfully partnered with several international top 10 pharmaceutical companies as well as various startups and university hospitals. To date, more than 4,500 autologous and allogeneic cell products have been released for clinical use since 2006, including 700 different autologous CAR-T cell products and CAR-T intermediate products.

Whether it's preclinical validation, GMP process development, or GMP manufacturing - we are your integrated partner in bringing new cell and gene therapies from lab scale to clinical practice and the market.

If you have any questions about cell and gene therapy development and manufacturing, I invite you to connect with us at ESGCT Congress 2026.